


OVERVIEW

Symple Surgical, Inc. (the “Company” or “SSI”) was established in 2012 with a vision of providing low-cost, minimally invasive, microwave ablation (“MWA”) technology. In 2016, SSI began its focus on treating Barrett’s Esophagus and Esophageal Adenocarcinoma (“EAC”) due to the potential advantages of MWA over the current standard of care. EAC, as a disease, is the fastest growing solid tumor cancer in the world, and SSI has developed a novel method of ablation using microwave frequencies to safely and effectively ablate Barrett’s Esophagus and subsequently eliminate EAC. This disease state has grown by over 800% over the last 30 years and represents a large market opportunity for new treatment methods.

The Company’s founder, Dan Kasprzyk, is a medical device engineer and serial entrepreneur with a track record of successful start-ups and exits. He has primarily funded the Company with approximately \$2.0 million, along with placing relevant intellectual property (IP) into the firm. The Company’s prior rounds of financing have raised approximately \$1.7 million in funding beyond that invested by Mr. Kasprzyk. The Company now seeks investors to fund the remaining capital needs for the next significant milestone, proof of concept. This includes prototyping of the GRIZZLY™ catheter, handle automation, antennae prototyping, and pre-clinical studies.

SSI’s microwave ablation method is superior to other ablation methods for treating Barrett’s Esophagus and EAC and provides the following:


- Larger ablation zone killing commonly missed deeper cells
- Microwave energy delivery that is independent of target tissue properties and is non-contact
- Dielectric heating creating a uniform heating method
- Potential for fewer follow-up procedures and less pain
- Ability for circumferential and directional ablations from a single device
- Microwave antennae for monitoring and emission of energy



To date, the Company’s engineering and Scientific Advisors have contributed initial concepts and designs to the Company. Intellectual property reviews were performed prior to forming the Company and eight (8) patent applications associated with the various alternatives have been submitted.

The Company has established initial development plans and timelines for the completion of prototypes, assessment of the alternatives, and starting both animal and FIM studies. SSI’s Management team has significant experience in completing the 510(K) process and successfully commercializing medical products. Below outlines Management’s product rollout plan with an initial focus on outpatient facilities:

Projected Monthly Microwave Ablation Procedures Performed by SSI Technology for Barrett’s Esophagus and EAC at Product Launch



TRANSACTION OPPORTUNITY

SSI is seeking \$1.5 million in capital to fund the development of the Grizzly™ microwave catheter, motorized ablation handle, and demonstration of proof of concept testing in a pre-clinical model utilizing Dr. Prasad Iyer and MAYO Clinic. The Company has retained Objective Capital Partners as its exclusive financial advisor to identify strategic and financial partners over the long term.

INVESTMENT HIGHLIGHTS AND DRIVERS

Large Market Opportunity with Increasing Demand. Barrett's Esophagus is a largely undiagnosed condition that typically results from repeated exposure to stomach acid, and according to the Mayo Clinic there are over 200,000 new cases in the U.S. alone every year. Barrett's Esophagus affects more than 12 million American adults and is associated with a 30-fold increased risk of developing EAC. Nearly 16,000 people will die in 2018 from EAC in the U.S. and another 280,000 worldwide.

Attractive Economics and Recurring Revenue. Each SSI microwave ablation generator sold represents approximately 40 procedures per month performed. The catheters required for use with the generators represent a significant recurring revenue opportunity with attractive margins:

SSI Economics			
Generator Revenue	\$15,000	Catheter ASP	\$1,895
Generator COGS	\$11,500	Catheter COGS	\$185
Gross Profit	\$3,500	Gross Profit	\$1,710

Performing 12,700 ablation procedures per month represents a \$24 million monthly recurring revenue opportunity

More Efficient Ablation Method. Controlled penetration of Microwave Energy should lead to fewer follow-up procedures and less pain for patients, saving time and cost. SSI's balloon based design is familiar and easy to use by medical practitioners and eliminates incorrect sizing by providing a device size for all patients. The GRIZZLY™ catheter is a focused sectional based emitter with unobstructed balloon walls that allow for better lesion visualization resulting in greater therapeutic accuracy and directional control targeting island and tongue lesions.

Patented Technology with Clear 510(k) Regulatory Path. The Company currently has one (1) issued and seven (7) filed patents across the entire Symple Surgical technology portfolio. Below outlines the Company's commercialization plan:

	2018				2019				2020				2021			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Product Development			Antennae Prototyping			Commercial Generator Development						Design Freeze				
	Catheter & Handle Automation Prototyping				Catheter & Handle Optimization											
Testing & Studies	Bench Testing				POC Study		GLP Study		GLP Study				FIM Study			
Regulatory						Pre-510(K)							510(K)	CE Mark	Post-Market Clinical Study	
Marketing & Sales													Publication and Conferences			Commercialization
Funding	\$1.5 million Series A					\$15 million Series B										

Please direct all inquiries and requests for information to the following individuals:

Jack J. Florio, BS Pharm, MBA
Managing Director
jack.florio@objectivecp.com
(858) 864-4339

David H. Crean, Ph.D.
Managing Director
david.crean@objectivecp.com
(858) 245-4905

This executive summary is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities or a solicitation of any such offer or invitation and shall not form the basis of any contract with the Company, Objective Capital Partners, LLC, or BA Securities, LLC. Further, the contents of this executive summary and any attachments, annexes or schedules hereto is preliminary, limited and subject to completion correction or amendment and should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person. The financial projections presented in this executive summary represent the subjective views of the management of the Company and management's current estimates of future performance based on various assumptions which management believes are reasonable, but which may or may not prove to be correct. David H. Crean and Jack Florio of Objective Capital Partners, are registered representatives of and Securities and Investment Banking Services are offered through BA Securities, LLC Member FINRA SIPC. Objective Capital Partners, LLC and BA Securities, LLC are separate and unaffiliated entities.